Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Ranbaxy Acquires New Responsibilities and About $100M through Expanded Alliance with GSK

  • Ranbaxy Laboratories gained additional development responsibilities and further financial opportunities through the expansion of its alliance with GlaxoSmithKline.

    Under the original 2003 agreement, Ranbaxy conducted the optimization chemistry required to progress drug leads to the stage of candidate selection. Under the new multiyear R&D agreement, Ranbaxy will advance leads beyond candidate selection to completion of clinical proof of concept. GSK thereafter will conduct further development for each program and take resulting products through the regulatory approval process to final commercialization.

    Ranbaxy could receive over $100 million in milestone payments and up to double-digit royalties on worldwide net sales. Ranbaxy will retain the right to co-commercialize the products in India. The new milestones and royalties will apply to the two programs ongoing at Ranbaxy, under the original agreement with GSK, as well as to future drug discovery programs.

    GSK says the expanded alliance could lead to potential work in a range of therapeutics, including anti-infectives and metabolic, respiratory, and oncology products.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »